NImmune Biopharma

Executive Summary

NImmune Biopharma is a late-clinical-stage precision immunology company developing first-in-class, oral, gut-restricted LANCL2 agonists for autoimmune diseases. Its lead candidate, omilancor, is currently in Phase 3 for ulcerative colitis (UC) and Phase 2 for Crohn's disease (CD). The company leverages an AI-driven platform to identify novel targets and accelerate drug development. Omilancor has demonstrated a favorable safety and efficacy profile in prior Phase 2 trials, with a unique mechanism of action that modulates immune responses locally in the gut. The upcoming Phase 3 UC trial results are a pivotal milestone that could support regulatory filings. Additionally, the Phase 2 CD program offers upside potential. As a private company, NImmune may also pursue strategic partnerships to advance its pipeline. The strong scientific rationale and clinical progress position omilancor as a potential best-in-class therapy for inflammatory bowel disease.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data for omilancor in ulcerative colitis70% success
• H1 2027Phase 2 data for omilancor in Crohn's disease60% success
• TBDStrategic partnership or financing round50% success